Awm Investment Company Inc decreased Ultra Clean Holdings Inc. (UCTT) stake by 15.64% reported in 2018Q3 SEC filing. Awm Investment Company Inc sold 140,909 shares as Ultra Clean Holdings Inc. (UCTT)’s stock declined 38.85%. The Awm Investment Company Inc holds 760,000 shares with $9.54 million value, down from 900,909 last quarter. Ultra Clean Holdings Inc. now has $353.08M valuation. The stock increased 0.11% or $0.01 during the last trading session, reaching $9.05. About 275,112 shares traded. Ultra Clean Holdings, Inc. (NASDAQ:UCTT) has declined 59.83% since January 15, 2018 and is downtrending. It has underperformed by 59.83% the S&P500. Some Historical UCTT News: 25/04/2018 – Ultra Clean Sees 2Q EPS 50c-EPS 59c; 02/05/2018 – Renewable Energy Group Launches REG Ultra Clean™ Diesel; 25/04/2018 – Ultra Clean 1Q EPS 66c; 15/05/2018 – Millennium Management LLC Exits Position in Ultra Clean
Inflarx N.V. (NASDAQ:IFRX) had a decrease of 1.57% in short interest. IFRX’s SI was 231,600 shares in January as released by FINRA. Its down 1.57% from 235,300 shares previously. With 11,900 avg volume, 20 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 3.2%. The stock increased 4.22% or $1.43 during the last trading session, reaching $35.29. About 14,993 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since January 15, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018
Since July 31, 2018, it had 1 insider buy, and 0 sales for $13,404 activity. MADDOCK ERNEST E had bought 1,000 shares worth $13,404 on Tuesday, July 31.
Among 2 analysts covering Ultra Clean Holdings (NASDAQ:UCTT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ultra Clean Holdings had 2 analyst reports since August 28, 2018 according to SRatingsIntel. The stock of Ultra Clean Holdings, Inc. (NASDAQ:UCTT) has “Buy” rating given on Tuesday, August 28 by Standpoint Research.
Investors sentiment decreased to 1.08 in Q3 2018. Its down 0.03, from 1.11 in 2018Q2. It turned negative, as 28 investors sold UCTT shares while 38 reduced holdings. 27 funds opened positions while 44 raised stakes. 30.65 million shares or 1.34% less from 31.07 million shares in 2018Q2 were reported. Tiaa Cref Investment Mngmt Limited Co reported 73,837 shares. Walleye Trading Limited Liability Com invested in 0.01% or 124,503 shares. Barclays Public Ltd Co reported 0% of its portfolio in Ultra Clean Holdings, Inc. (NASDAQ:UCTT). Gradient Invests Limited Liability Corporation holds 0.04% or 66,083 shares in its portfolio. Riverhead Cap Ltd Liability Company reported 4,900 shares. Bnp Paribas Arbitrage holds 1,233 shares or 0% of its portfolio. Trexquant Investment Lp stated it has 14,337 shares or 0.01% of all its holdings. Moreover, Next Fin Grp Inc has 0.03% invested in Ultra Clean Holdings, Inc. (NASDAQ:UCTT). Goldman Sachs Group owns 174,638 shares. Thomson Horstmann & Bryant reported 0.45% in Ultra Clean Holdings, Inc. (NASDAQ:UCTT). Engineers Gate Manager Lp accumulated 90,817 shares. State Of Alaska Department Of Revenue holds 0% or 12,670 shares. Northern Corp holds 444,330 shares or 0% of its portfolio. Susquehanna Gru Llp has 0% invested in Ultra Clean Holdings, Inc. (NASDAQ:UCTT). Victory Inc holds 0% or 16,426 shares in its portfolio.
Analysts await Ultra Clean Holdings, Inc. (NASDAQ:UCTT) to report earnings on February, 20. They expect $0.25 earnings per share, down 57.63% or $0.34 from last year’s $0.59 per share. UCTT’s profit will be $9.75M for 9.05 P/E if the $0.25 EPS becomes a reality. After $0.30 actual earnings per share reported by Ultra Clean Holdings, Inc. for the previous quarter, Wall Street now forecasts -16.67% negative EPS growth.
More notable recent Ultra Clean Holdings, Inc. (NASDAQ:UCTT) news were published by: Nasdaq.com which released: “5 Quality Tech Stocks At Bargain Prices – Nasdaq” on December 26, 2018, also Streetinsider.com with their article: “Needham & Company Starts Ultra Clean (UCTT) at Buy – StreetInsider.com” published on December 21, 2018, Nasdaq.com published: “Bear of the Day: Ultra Clean Holdings (UCTT) – Nasdaq” on August 09, 2018. More interesting news about Ultra Clean Holdings, Inc. (NASDAQ:UCTT) were released by: Seekingalpha.com and their article: “Fresh Data-Based Insight On Ultra Clean Holdings – Seeking Alpha” published on November 06, 2018 as well as Seekingalpha.com‘s news article titled: “Ultra Clean Holdings: Increasing Demand, Solid Fundamentals Make This Semiconductor Stock An Ideal Growth Candidate – Seeking Alpha” with publication date: May 25, 2018.
Awm Investment Company Inc increased American Superconductor stake by 243,154 shares to 1.50M valued at $10.40 million in 2018Q3. It also upped Sensus Healthcare Inc stake by 170,000 shares and now owns 661,938 shares. Adesto Technologies Corp. was raised too.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “InflaRx Continues US Expansion with Addition of New York City Corporate Office and Addition of Management – Nasdaq” on January 03, 2019, also Nasdaq.com with their article: “InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – Nasdaq” published on December 19, 2018, Nasdaq.com published: “Shaw Announces First Quarter Fiscal 2019 Results – Nasdaq” on January 14, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Alamos Reports Fourth Quarter 2018 Production and Provides 2019 Outlook – Nasdaq” published on January 14, 2019 as well as Nasdaq.com‘s news article titled: “Can Solid Product Portfolio Aid Atlassian (TEAM) Q2 Earnings? – Nasdaq” with publication date: January 14, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $905.62 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.